Revolution Medicines Inc at Goldman Sachs Healthcare Conference Transcript
Good morning, everybody. Welcome to Wednesday. Great to see people here at the Goldman Sachs Healthcare Conference, 44th addition. My name is Chris Shibutani, member of the research team. Team is including some terrific associates, Charlie Ferranti is up here me.
The good doctor will also be involved with making sure we prosecute the details and the questions. Revolution absolutely pleased that you guys could be here once again. And we have on the stage with us Peg Horn, Chief Operating Officer; and Steve Kelsey. President of R&D. Professor Steve last year did a didactic. I think we'll have a sort of like next 2023 addition of that to happen this year. So this space that you guys are engaged in with the targeted therapies in oncology focus, there's so many chapters seasons, arcs, right? And I think you guys -- we've known each other for many years, even before the IPO, and thinking about that, the inherent excitement in terms of being able to capture a potential opportunity that everybody had known about in terms
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |